COMMUNIQUÉS West-GlobeNewswire

-
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
21/03/2025 -
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
21/03/2025 -
Bright Green Corporation Announces the next steps for the completion of its restructuring plan
21/03/2025 -
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
21/03/2025 -
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
21/03/2025 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
21/03/2025 -
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
21/03/2025 -
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
21/03/2025 -
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
21/03/2025 -
TOMI Environmental Solutions Expands into Aquaculture with New Partner, Algafeed
21/03/2025 -
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
21/03/2025 -
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
21/03/2025 -
Vireo Growth Inc. Files Definitive Information Circular and Provides Merger Transaction Updates
21/03/2025 -
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
21/03/2025 -
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
21/03/2025 -
Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030
21/03/2025 -
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
21/03/2025 -
Conavi Medical Corp. Announces Upsize to its Previously Announced Public Offering
21/03/2025 -
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
21/03/2025
Pages